Replies to post #2089 on Enanta Pharmaceuticals Inc (ENTA)

[DewDiligence]

Do you think ENTA will advance EDP-514 in trials in combination with a nuc, at least for now?

They already completed a phase-1b combination trial of EDP-514 with a nuc (the trial that enrolled “viremic” patients) without any problems, so I presume they will advance the combination to phase-2.

I sure hope ENTA has other [than RNA-destabilizer] HepB targets in mind.

That’s a good bet; Jay Luly has spoken of multiple (undisclosed) HBV mechanisms in the discovery phase. What’s needed is something that is highly active against the sub-viral particles responsible for emitting HBsAg.

[DewDiligence]

Looks like I was wrong about, “pretty modest.”